Details of the Drug

General Information of Drug (ID: DMMQFG2)

Drug Name

Imeglimin

Synonyms

775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 2	[1]
Type-2 diabetes	5A11	Phase 2	[2]
------------------------------------------------------------------------------------

ATC Code

A10BX15: Imeglimin

A10BX: Other blood glucose lowering drugs, excl. insulins

A10B: BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

A10: DRUGS USED IN DIABETES

A: ALIMENTARY TRACT AND METABOLISM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

155.2

Logarithm of the Partition Coefficient (xlogp)

-1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C6H13N5
IUPAC Name: (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine
Canonical SMILES: C[C@@H]1N=C(NC(=N1)N(C)C)N
InChI: InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
InChIKey: GFICWFZTBXUVIG-SCSAIBSYSA-N

Cross-matching ID

PubChem CID: 24812808
CAS Number: 775351-65-0
UNII: UU226QGU97
DrugBank ID: DB12509
TTD ID: D08PMB

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
AMP-activated protein kinase (AMPK)	TTLAFZV	AAPK1_HUMAN ; AAKB1_HUMAN ; AAKG1_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
2	ClinicalTrials.gov (NCT01951235) A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)